Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 175,986
  • Shares Outstanding, K 246,237
  • Annual Sales, $ 1,200 K
  • Annual Income, $ -177,120 K
  • EBIT $ -211 M
  • EBITDA $ -209 M
  • 60-Month Beta 1.07
  • Price/Sales 146.17
  • Price/Cash Flow N/A
  • Price/Book 0.99
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.75
  • Most Recent Earnings $-0.18 on 11/12/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 236.77% ( -15.40%)
  • Historical Volatility 113.74%
  • IV Percentile 94%
  • IV Rank 62.25%
  • IV High 369.24% on 12/18/24
  • IV Low 18.27% on 01/11/24
  • Put/Call Vol Ratio 0.08
  • Today's Volume 892
  • Volume Avg (30-Day) 1,367
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 36,743
  • Open Int (30-Day) 35,458

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.11
  • Number of Estimates 4
  • High Estimate -0.08
  • Low Estimate -0.16
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +45.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6204 +33.30%
on 12/05/24
1.0200 -18.92%
on 12/11/24
-0.0364 (-4.22%)
since 11/22/24
3-Month
0.6204 +33.30%
on 12/05/24
2.1750 -61.98%
on 10/18/24
-0.7530 (-47.66%)
since 09/23/24
52-Week
0.6204 +33.30%
on 12/05/24
3.7300 -77.83%
on 02/16/24
-0.4830 (-36.87%)
since 12/22/23

Most Recent Stories

More News
Lexicon Announces Receipt of Complete Response Letter for Zynquistaâ„¢ (sotagliflozin)

LXRX : 0.8270 (+15.71%)
2 Generic Drug Stocks Ready to Surge in 2025

Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.

LXRX : 0.8270 (+15.71%)
VTRS : 12.49 (-0.24%)
TEVA : 22.21 (+0.54%)
AMGN : 264.00 (+0.24%)
PFE : 26.71 (+1.33%)
Lexicon Pharmaceuticals Completes Patient Enrollment for PROGRESS Study of LX9211, Exceeding Targets by 20%

Lexicon Pharmaceuticals exceeded enrollment targets in its PROGRESS study of LX9211 for diabetic peripheral neuropathic pain, aiming for Q1 2025 data.Quiver AI SummaryLexicon Pharmaceuticals announced...

LXRX : 0.8270 (+15.71%)
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

LXRX : 0.8270 (+15.71%)
Lexicon Pharmaceuticals to Participate in December Investor Conferences

LXRX : 0.8270 (+15.71%)
Lexicon Pharmaceuticals Announces Strategic Restructuring to Focus on R&D and Cut Operating Costs by $100 Million

Lexicon Pharmaceuticals is restructuring to eliminate commercial operations, focusing on R&D, expecting $100 million in cost savings by 2025.Quiver AI SummaryLexicon Pharmaceuticals, Inc. has announced...

LXRX : 0.8270 (+15.71%)
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

LXRX : 0.8270 (+15.71%)
Ivan H. Cheung Elected to Board of Directors of Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals announces Ivan H. Cheung’s election to its Board of Directors, highlighting his extensive biopharmaceutical experience.Quiver AI SummaryLexicon Pharmaceuticals, Inc. has announced...

LXRX : 0.8270 (+15.71%)
Lexicon Appoints Ivan H. Cheung to Board of Directors

LXRX : 0.8270 (+15.71%)
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago

LXRX : 0.8270 (+15.71%)

Business Summary

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones....

See More

Key Turning Points

3rd Resistance Point 1.1027
2nd Resistance Point 0.9728
1st Resistance Point 0.8999
Last Price 0.8270
1st Support Level 0.6971
2nd Support Level 0.5672
3rd Support Level 0.4943

See More

52-Week High 3.7300
Fibonacci 61.8% 2.5421
Fibonacci 50% 2.1752
Fibonacci 38.2% 1.8083
Last Price 0.8270
52-Week Low 0.6204

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar